Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of
Ashish Kyal of Waves Strategy Advisors advises buy
Prakash Gaba of prakashgaba.com is of the view tha
Ashwani Gujral of ashwanigujral.com advises buying
The CMD of Biocon Ltd, which was rated among the w